As part of its quarterly update to shareholders, Cronos Group (TSXV:CRON,NASDAQ:CRON) reported growth in sales thanks to cannabis oils and increased production capacity. 

On Monday (April 30), the company issued its Q4 and 2017 fiscal financial results for the period ended on December 31, 2017.


During the fourth quarter, Peace Naturals, Cronos’ wholly owned licensed producer (LP), obtained a dealer’s license, allowing it to export medical cannabis extracts.

Peace Naturals has continued to receive upgrades to its production facilities. A fourth expansion is in the works for Cronos, and the company said it expects to start work for it in the second half of 2018.

Cronos reported C$1.6 million in sales during Q4 and total 2017 fiscal year sales of C$4.1 million.

The company credited its sales increase during the fourth quarter in part to the bigger production capabilities it now holds, as well as an increase in business-to-business sales to other LPs in Canada and abroad and to the increased market share of cannabis oils.

According to Cronos’ documents, cannabis oil sales equaled 21 percent of its domestic sales with consumers. Last December, these oils saw sales growth of 257 percent month-over-month.

The total cost of sales for the 2017 fiscal year decreased by C$1.7 million for the company compared to the 2016 fiscal year. On the other hand, Cronos’ operating expenses increased to C$9.3 million.

During the quarter, Cronos achieved something no other Canadian LP has done: the company put its public stock on the NASDAQ Stock Exchange. The announcement caused a new wave of legitimacy to rush across the industry.

Recreational market is on the way and Cronos plans to expand for it

On the Cronos conference call to discuss these results, Martin Landry, cannabis analyst with GMP Securities, asked if the company is planning to use its fourth expansion for recreational market purposes and if the company is stashing product to be sold once recreational becomes available.

Mike Gornstein, CEO of Cronos, answered by first saying that most people would like to know when day one of recreational sales will actually be.

“Because of the uncertain timing and because of the need to serve international channels and medical patients we are trying to maintain some level of safety stock,” he explained.

However, Gornstein added that the company still wants to guarantee having a turn through of that inventory. “We want to make sure the product is always fresh,” he said.

Gornstein said the fourth building is on track to have plants for July, making it possible for the company to push product if legalization in Canada arrives earlier.

“We are not pre-packing inventory when it comes to actually saving because of the lack of clarity on packaging [regulations],” Gornstein explained. The company currently has two iterations of the packaging it expects to use for recreational products and is waiting for Health Canada’s ruling.

As a way to continue its expansion, Cronos raised C$100 million from GMP Securities, BMO Capital Markets and a grouping of Cormark Securities, Beacon Securities and PI Financial.

Cronos will use C$15 million of the funds for expenses on its international operations and capacity expansion. The rest will be used for the everyday general working purposes.

Investor takeaway

Cannabis analyst Landry issued a report following Cronos’ capital raising earlier this month in which he lowered his target price for the company to C$9 per share.

“With a reinvigorated balance sheet, Cronos has the munitions to increase capacity or make tactical investments,” Landry wrote, according to Cantech Letter.

Landry used this note to upgrade his recommendation on the company from “hold” to “buy.” He added that Cronos is in a better position in terms of the recreational market in Canada thanks to a new partnership with US retailer operator MedMen.

Cronos started trading on the NASDAQ on February 27. Since then, the stock’s value has decreased by 10.76 percent. On Monday, the company closed at US$6.91 on the exchange, representing a 1.62-percent increase from its previous closing price.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less